drugset / Trial / NCT03839524
A Trial Evaluating TG4050 in Ovarian Carcinoma.
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, single arm phase I study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with ovarian, fallopian or peritoneal serous carcinoma.
Timeline
- Start
- 2019-12-09
- Primary completion
- 2024-10-08
- Completion
- 2024-10-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TG4050 | Unknown | — | Subcutaneous |